The Asilomar Conference of 1975 and the German Ethics Council offer guidance for a path towards prudent regulation in the face of unknown and significant risks.
AMA J Ethics. 2019;21(12):E1042-1048. doi:
10.1001/amajethics.2019.1042.
Although advisory groups like the World Health Organization question whether certain forms of gene editing should be permitted, the US Patent Office routinely issues patents protecting this technology.
AMA J Ethics. 2019;21(12):E1049-1055. doi:
10.1001/amajethics.2019.1049.
Clinically and ethically relevant questions are related to patient safety, therapeutic efficacy, equitable access, and global governance over humanity’s genetic legacy.
AMA J Ethics. 2019;21(12):E1079-1088. doi:
10.1001/amajethics.2019.1079.
International debate about human genome editing governance has undergone a paradigm shift and suggests that inclusive public deliberation is still important.
AMA J Ethics. 2019;21(12):E1065-1070. doi:
10.1001/amajethics.2019.1065.